Results 61 to 70 of about 5,627 (198)

Immunotoxin therapy: a promising frontier in targeted cancer treatment a review of clinical trials in hematological and solid tumors

open access: yesCancer Treatment and Research Communications
Background and objective: Background and objective: Cancer is a leading cause of death worldwide, creating a major socioeconomic burden. Despite advances in conventional therapies, mortality remains high, highlighting the need for more effective ...
Arash Abdi   +5 more
doaj   +1 more source

Regulation of PD‐1PD‐L1 Immune Checkpoints by Gut Microbiota Metabolites and Their Clinical Translational Research: A Review

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 7, July 2026.
ABSTRACT Background Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 pathway have revolutionized cancer immunotherapy, yet their clinical benefit is constrained by variable response rates and immune‐related adverse events. Aims This review systematically analyzes the molecular mechanisms by which key gut microbiota‐derived metabolites ...
Xuanyou Fang, Shuai Yuan, Weijian Mai
wiley   +1 more source

De Novo Synthesis in Cancer Immunotherapy: Applications and Prospects

open access: yesMedComm, Volume 7, Issue 7, July 2026.
De novo protein design creates novel structures for cancer immunotherapy, integrating rational design principles like modularity and specificity. Leveraging computational tools, it optimizes cytokine engineering, adoptive cellular therapy, and checkpoint regulation to enhance antitumor immunity.
Yang Jin, Yanfeng Wu, Jianhua Luo
wiley   +1 more source

Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins. [PDF]

open access: yesPLoS ONE, 2016
The intersection of small molecular weight drugs and antibody-based therapeutics is rarely studied in large scale. Both types of agents are currently part of the cancer armamentarium.
Antonella Antignani   +11 more
doaj   +1 more source

Targeted Diphtheria Toxin-Based Therapy: A Review Article

open access: yesFrontiers in Microbiology, 2019
Cancer remains one of the leading causes of death worldwide. Conventional therapeutic strategies usually offer limited specificity, resulting in severe side effects and toxicity to normal tissues.
Fatemeh Shafiee   +2 more
doaj   +1 more source

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

open access: yesMedicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca   +6 more
wiley   +1 more source

In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins

open access: yes, 2000
Immunotoxins specific for the CD80 and CD86 antigens were prepared by linking three type 1 ribosome-inactivating proteins (RIPs), namely bouganin, gelonin and saporin-S6, to the monoclonal antibodies M24 (anti-CD80) and 1G10 (anti-CD86).
Polito L.   +8 more
core   +1 more source

Inclusion of a Furin Cleavage Site Enhances Antitumor Efficacy against Colorectal Cancer Cells of Ribotoxin α-Sarcin- or RNase T1-Based Immunotoxins

open access: yesToxins, 2019
Immunotoxins are chimeric molecules that combine the specificity of an antibody to recognize and bind tumor antigens with the potency of the enzymatic activity of a toxin, thus, promoting the death of target cells.
Javier Ruiz-de-la-Herrán   +4 more
doaj   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, Volume 13, Issue 35, 24 June 2026.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Delivering Proteins and Enzymes to Solid Tumors Through the Development of Stimuli‐Responsive Nanocarriers

open access: yesChemNanoMat, Volume 12, Issue 6, June 2026.
Stimuli‐responsive strategies to achieve controlled release of protein‐based therapeutic agents into solid tumors. Proteins, enzymes, and peptides have long been recognized as valuable therapeutic agents, particularly in oncology. However, their complex chemical structures render them more sensitive than smaller chemotherapeutic drugs.
Guillermo Plaza‐Palomo   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy